BPH, Cancers Linked to Peyronie's Disease

Share this content:
Men with Peyronie's disease have elevated risks of benign prostatic hyperplasia, prostatitis, and testis and prostate cancer, new studies reveal.
Men with Peyronie's disease have elevated risks of benign prostatic hyperplasia, prostatitis, and testis and prostate cancer, new studies reveal.
The following article is part of conference coverage from the 2018 American Urological Association meeting in San Francisco. Renal and Urology News' staff will be reporting live on medical studies conducted by urologists and other specialists who are tops in their field in kidney stones, prostate cancer, kidney cancer, bladder cancer, enlarged prostate, and more. Check back for the latest news from AUA 2018. 

SAN FRANCISCO—Men with Peyronie's disease (PD) are at higher risk of enlarged prostate, prostatitis, and various malignancies, including testis, prostate, and stomach cancer, investigators reported at the American Urological Association 2018 annual meeting.

The findings are from separate studies by the same research team led by Alexander W. Pastuszak MD, PhD, of Baylor College of Medicine in Houston. In one study, the investigators included 8738 men with PD, 204,147 men with erectile dysfunction (ED), and 87,280 controls without PD or ED matched by age and follow-up duration. Compared with men in the ED and control group, men in the PD group had a 21% increased risk of benign prostatic hyperplasia (BPH), 21% increased risk of prostatitis, and 10% increased risk of lower urinary tract symptoms (LUTS). In addition, compared with controls, PD patients had an elevated risk of developing keloids. The study found no association between PD and risk of any autoimmune disease.

“Men with PD have an increased risk of developing BPH, LUTS, prostatitis and keloids,” the authors concluded in their study abstract. “This may be related to myofibroblast activity, and these findings support a common etiology for these conditions that may manifest at different points during the male life cycle.”

The other study included 48,423 men with PD, 1,177,428 with ED, and 484,230 controls. The PD patients were matched by age and duration of follow-up with the ED patients and controls. The mean age of all 3 cohorts was 49 years, and the mean follow-up time was 4.4 years. Compared with controls, the patients with PD had a significant 39% and 43% increased risk of testis and stomach cancer, respectively, and a 19% increased risk of melanoma. Compared with men who had ED, those with PD had a 38% increased risk of prostate cancer.

The authors also performed whole exome sequencing on a father and son with both PD and Dupuytren's disease, a related fibrotic disorder, and identified numerous shared mutations that may also be involved in gastrointestinal and genitourinary cancers. 

Visit Renal and Urology News' conference section for continuous coverage from AUA 2018.

Reference

Pastuszak AW, Rodriguez KM, Kohn TP et al. Increased risk of BPH, lower urinary tract syndromes, prostatitis, and keloids in men with Peyronie's disease: Analysis of United States Claims Data. Data presented in poster format the American Urological Association 2018 annual meeting, San Francisco, May 18–21. Abstract: MP04-20.

Pastuszak AW, Kohn TP, Eisenberg, ML, et al. Increased risk of cancer in men with Peyronie's disease. Oral presentation at the American Urological Association 2018 annual meeting, San Francisco, May 18–21.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters